Wall Street Trader schreef op 18 september 2020 17:30:
[...]
Onno's words were the end of this month.There are several triggers to recover again and those are probably coming in the next couple of weeks. The upcoming catalysts are very important.
Let's focus on the future and upcoming catalysts!2020 newsflow
• Filgotinib Anticipated approval decisions for filgotinib in RA: Europe (probably next week) GLPG is due $75M on approval in the EU.
A decision from Japanese authorities is expected in October.
GLPG is due $30M on approval in Japan.
• PINTA ‘1205 Ph2a IPF (Q4)• ROCCELLA ‘1972 Ph2b OA (Q4)1972 received fast track status! Triggering a 60-day opt-in period for Gilead for US rights.
For GLPG1972, Gilead has the option to pay a $250 million fee to license the compound in the United States after the completion of the ongoing Phase 2b study in osteoarthritis. If certain secondary efficacy endpoints are met, Gilead would pay up to an additional $200 million. Following opt in, Galapagos would be eligible to receive up to $550 million in regulatory and commercial milestones.
• TOLEDO (Q4, likely on R&D Day)A lot of preclinical data will be announced and revealed including the target and pathway of the Toledo compounds.
Start of 5 Phase 2 studies with GLPG3970 with anticipated readout 1H21
Investor Relations slides | August 2020www.glpg.com/docs/view/5f455cc855420-enOnno van de Stolpe: We have a fantastic pipeline with a number of potentially blockbuster molecules moving towards the market. The true innovation, based on a unrivaled target discovery platform, has already delivered new mode of actions into late stage clinical trials, and has the promise to address further diseases with high unmet medical needs. The $ ~6 billion cash pile enables us to make the right decisions for the projects, not hindered by funding concerns. This increases the chance of further success. And that combined with the guaranteed 10-year independence as part of the Gilead deal, makes me a strong believer in the potential to grow out into one of the leading biotech companies in the world.